1522361-80-3

Upstream product

• 1522361-72-3 (E)-1-(2,4-bis(allyloxy)-5-chlorophenyl)-3-(3,4-bis(allyloxy)phenyl)prop-2-en-1-one 
• 71186-67-9 3,4-diallyloxybenzaldehyde 
• 1522361-77-8 1-(2,4-bis(allyloxy)-5-chlorophenyl)ethanone 
• 90110-32-0 1-(5-chloro-2,4-dihydroxyphenyl)ethan-1-one 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 

Relevant academic research and scientific papers

New chalcone compound or pharmaceutically acceptable salt thereof having inhibitory activity on Hsp90 and medical use thereof

The present invention relates to a novel chalcone compound or pharmaceutically acceptable salt thereof having inhibitory activity on Hsp90, and to medical use thereof. The charcone compound: has an excellent effect of inhibiting Hsp90; induces decomposition of Hsp90 client protein, which causes cancer or neurodegenerative diseases; and thus can be advantageously used for a pharmaceutical product or health-promotional food for treating or preventing Hsp90-mediated diseases such as cancer or neurodegenerative diseases. The chalcone compound or the pharmaceutically acceptable salt is represented by Chemical Formula 1 below.

Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC)

Heat shock protein 90 (Hsp90) represents an attractive cancer therapeutic target due to its role in the stabilization and maturation of many oncogenic proteins. We have designed a series of hybrid Hsp90 inhibitors by connecting the resorcinol ring of VER-